Immunocore Reports Q2 2026 Financial Results: KIMMTRAK Sales Up 18%
Immunocore Holdings announced $115.9M in Q2 2026 sales for KIMMTRAK, a 18% year-over-year increase. The company reported improved net income for the H1 and provided updates on Phase 3 clinical trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day